1. Meaning of specimen ownership

A biological specimen may include:

• blood and serum;
• urine and other bodily fluids;
• hair, nails and epithelial material;
• tissue/biopsy specimens;
• organs or parts of organs;
• DNA extracted from biological material;
• sperm and ova;
• embryos;
• fetal tissue;
• pathology slides and blocks;
• cell lines;
• samples stored in biobanks.

The Indian Council of Medical Research (ICMR) expressly recognizes biological materials ranging from biological fluids and dried blood spots to tissues and organs, and identifies ownership, transfer, custodianship, secondary use and return of results as distinct legal/ethical issues.

The difficult legal question is:

Who has the legal right to possess, control, transfer, destroy, research upon, or commercially exploit a biological specimen after it has been removed from the human body?

There is no single universal answer. It depends upon the purpose for which the specimen was collected, the consent given, applicable legislation, the relationship between donor and institution, and the nature of the specimen.

2. Ownership is different from custody

This distinction is fundamental.

Suppose a patient gives blood to a hospital.

The hospital may have:

Physical custody of the blood sample.

But that does not necessarily mean that the hospital has unlimited:

ownership + research rights + commercial rights + right to disclose genetic information.

For litigation, therefore, one should separately ask:

1. Who owns the specimen?
2. Who has physical possession?
3. Who is its legal custodian?
4. Who may authorize testing?
5. Who may transfer it?
6. Who may destroy it?
7. Who may use it for secondary research?
8. Who controls the information derived from it?
9. What did the consent form say?

3. Indian position: ICMR Guidelines are extremely important

The most significant Indian guidance comes from the ICMR National Ethical Guidelines for Biomedical and Health Research Involving Human Participants.

The ICMR framework specifically addresses biological materials, biobanking and datasets.

The 2018 ICMR handbook states that:

• participants own their biological samples/data;
• biobanks and institutions act as custodians/trustees;
• donors may ask for destruction/withdrawal of collected samples;
• informed consent should address future use;
• commercial value and benefit sharing should be disclosed where applicable; and
• material transfer agreements should be used for transfer of biospecimens. 

This is a very important Indian position.

Therefore:

Participant → owner

Institution/biobank → custodian/trustee

rather than simply:

Hospital → absolute owner

However, this must be approached carefully because ICMR ethical guidelines are not equivalent to a comprehensive statutory property code governing every specimen.

4. Consent is central to specimen litigation

Consent may determine what happens to the specimen after collection.

For example, a consent form may state:

“The sample may be stored and used for future research.”

That is materially different from:

“The sample will be used only for diagnosis.”

It is also different from:

“The sample may be transferred to third-party researchers.”

Consequently, in litigation, the court may examine:

• informed-consent form;
• patient-information sheet;
• research protocol;
• ethics-committee approval;
• material-transfer agreement;
• hospital policy;
• biobank terms;
• purpose for which the specimen was collected.

ICMR guidance recognizes different forms of consent, including broad, tiered, specific, delayed, dynamic, waiver and re-consent models.

5. Secondary use of specimens

A particularly important dispute arises when:

A specimen was collected for one purpose but subsequently used for another.

Example

A patient's blood is collected for diagnosis.

Later, the hospital wants to use the remaining blood for genetic research.

The legal/ethical issue becomes:

Did the original consent authorize this secondary use?

If not, questions arise regarding:

• consent;
• privacy;
• confidentiality;
• research ethics;
• institutional authority;
• data protection;
• potential commercialization.

The ICMR framework specifically recognizes secondary use of stored samples and datasets as an issue requiring appropriate consent/ethical consideration.

6. Landmark Indian case: Rohit Shekhar v. Narayan Dutt Tiwari

Rohit Shekhar v. Narayan Dutt Tiwari, Delhi High Court, 27 April 2012, is important for understanding litigation involving biological samples and DNA testing.

The case involved a dispute over paternity. The plaintiff sought a DNA test to establish whether Narayan Dutt Tiwari was his biological father.

The Court considered:

• the right to establish biological parentage;
• privacy;
• Article 21;
• the evidentiary value of DNA testing;
• the power of the civil court to direct scientific testing.

The Court recognized that a DNA test can be ordered in appropriate circumstances rather than treating such testing as automatically impermissible.

The case is especially relevant because it demonstrates that a biological sample can become an object of judicial direction in civil litigation.

7. Narayan Dutt Tiwari v. Rohit Shekhar

The matter subsequently reached the Supreme Court.

The Supreme Court did not interfere with the direction for DNA testing and gave specific directions for confidential collection of the blood sample and its transmission under seal to the testing laboratory.

This is important for specimen litigation because it demonstrates the concept of:

controlled judicial custody

The specimen was not simply handed over to one party.

Instead, the Court established a chain:

collection → sealing → authorized transportation → laboratory → report → Court

This protects:

• authenticity;
• confidentiality;
• chain of custody;
• evidentiary integrity.

8. Sharda v. Dharmpal

The Supreme Court in Sharda v. Dharmpal, (2003) 4 SCC 493 dealt with the question of medical examination in matrimonial litigation.

The Court recognized that a direction for medical examination does not automatically violate the right to privacy and that courts possess powers in appropriate circumstances to obtain medical evidence.

The principle is relevant to biological specimens because the right to privacy is not absolute when a legitimate judicial purpose exists.

However, a court must balance:

privacy of the individual

against

necessity of scientific evidence for adjudication.

9. Goutam Kundu v. State of West Bengal

In Goutam Kundu v. State of West Bengal, (1993) 3 SCC 418, the Supreme Court adopted a cautious approach toward compelling blood tests in paternity proceedings.

The Court emphasized that blood/DNA testing should not be ordered routinely or merely because one party asks for it.

This principle remains important:

A biological specimen cannot be demanded as a matter of unrestricted entitlement merely because it may help one party's case.

The court must consider the legal necessity, circumstances and consequences of the test.

10. Bhabani Prasad Jena v. Convenor, Orissa State Commission for Women

In Bhabani Prasad Jena v. Convenor, Orissa State Commission for Women, (2010) 8 SCC 633, the Supreme Court again emphasized caution in ordering DNA tests.

The Court balanced:

• scientific accuracy;
• privacy;
• dignity;
• presumption of legitimacy;
• interests of the child;
• necessity for adjudication.

The important proposition is:

DNA testing is powerful evidence, but scientific accuracy alone does not mean that a court must order testing in every case.

11. Aparna Ajinkya Firodia v. Ajinkya Arun Firodia

The Supreme Court has continued to emphasize that DNA testing should not become a routine instrument for matrimonial litigation where it could adversely affect the interests and dignity of a child.

This reflects a broader principle:

Biological truth is important—but it is not always the only legally relevant consideration.

Thus, specimen litigation requires balancing:

truth-seeking + privacy + dignity + welfare + proportionality.

12. The major foreign case: Moore v. Regents of the University of California

This is one of the world's most famous specimen-ownership cases.

Moore v. Regents of the University of California, 51 Cal. 3d 120, 793 P.2d 479 (1990).

Facts

John Moore was treated for leukemia.

During treatment, doctors removed cells from his body.

Those cells had unusual characteristics and became valuable for research.

Researchers developed a commercially valuable cell line from Moore's biological material.

Moore alleged that he had not been adequately informed of the researchers' interests and sought remedies including conversion based on ownership of his cells.

Decision

The California Supreme Court rejected his conversion/property claim but allowed a claim based on the physician's failure to disclose relevant interests.

In other words:

Moore did not succeed simply by saying, “These cells came from my body, therefore I own the resulting commercially valuable cell line.”

But the Court recognized the importance of the physician's disclosure obligations.

Significance

Moore demonstrates an important distinction:

Property claim ≠ informed-consent claim.

Even if a patient cannot establish conventional ownership sufficient for a conversion action, the patient may have a strong claim based upon:

• inadequate disclosure;
• breach of fiduciary duty;
• lack of informed consent;
• misuse of confidential information.

13. Washington University v. Catalona

This is perhaps the clearest direct specimen ownership litigation case.

Washington University v. Catalona, 490 F.3d 667 (8th Cir. 2007).

Facts

Dr. William Catalona was a researcher at Washington University.

Over many years, blood and tissue samples were collected from thousands of research participants for prostate-cancer research.

When Dr. Catalona left Washington University for another university, a dispute arose concerning who owned the specimens.

Thousands of participants had signed forms supporting transfer of their samples to Dr. Catalona.

Issue

Could the donors direct the university to transfer the specimens to the departing researcher?

Decision

The court held that Washington University owned the biological materials under the circumstances.

The court treated the donors' voluntary contributions as inter vivos gifts under Missouri law.

The donors therefore did not retain a property right enabling them to direct the transfer of the samples to another research institution.

Importance

This case demonstrates that specimen ownership may depend heavily upon:

• consent documents;
• intention of the donor;
• institutional arrangements;
• terms under which specimens were contributed;
• applicable state property law.

14. Greenberg v. Miami Children's Hospital

Another important case is:

Greenberg v. Miami Children's Hospital Research Institute, Inc., 264 F. Supp. 2d 1064 (S.D. Fla. 2003).

Families affected by Canavan disease provided biological material and information to facilitate research.

The research resulted in development of a genetic test.

The plaintiffs challenged the researchers' conduct and asserted various claims concerning control over the research and genetic material.

The court rejected several theories based upon ownership/control of the donated biological materials.

Significance

Greenberg illustrates the difficulty of transforming:

“I donated my biological material”

into:

“I retain an enforceable proprietary interest in everything subsequently developed from it.”

15. Yearworth v. North Bristol NHS Trust

The English position is particularly interesting because it reached almost the opposite conclusion in a specific context.

Yearworth v. North Bristol NHS Trust, [2009] EWCA Civ 37.

Facts

Cancer patients deposited sperm with a hospital before undergoing treatment that could make them infertile.

The hospital stored the sperm.

The storage system failed and the sperm was destroyed/damaged.

Issue

Could the patients claim that the sperm was their property?

Decision

The Court of Appeal held that, for the relevant negligence/bailment purposes, the sperm was property belonging to the persons who produced it.

The hospital could therefore face liability for failing to preserve it properly.

Significance

This case is very important because it demonstrates:

Not every biological specimen is necessarily treated as legally incapable of being property.

Context matters.

Frozen sperm held specifically for future reproductive use was treated differently from research tissue donated for scientific research.

16. Comparison of major cases

17. Indian law versus foreign law

A crucial point for examinations is that foreign cases cannot simply be transplanted into Indian law.

For example:

Catalona

The court applied Missouri property law and found a gift to the university.

Yearworth

The English Court of Appeal applied English property/bailment principles to stored sperm.

Moore

The California Supreme Court interpreted California property and tort law.

Therefore, these are persuasive comparative authorities, not automatically binding Indian precedents.

18. Indian legal position: a useful synthesis

For an Indian court, specimen ownership litigation can be analyzed through several layers.

Layer 1 — Consent

What did the donor agree to?

Layer 2 — Purpose

Why was the sample collected?

• diagnosis?
• treatment?
• forensic investigation?
• paternity?
• research?
• fertility preservation?

Layer 3 — Custody

Who currently possesses it?

Layer 4 — Property

Does the applicable law recognize a proprietary interest in that particular biological material?

Layer 5 — Privacy

Does its use reveal highly personal information?

Layer 6 — Scientific evidence

Is the specimen necessary for deciding the case?

Layer 7 — Public interest

Would restricting its use interfere with:

• criminal investigation;
• medical research;
• public health;
• identification;
• justice?

19. Specimen ownership in criminal litigation

Criminal cases present a different situation.

Suppose police recover:

• blood;
• semen;
• hair;
• saliva;
• tissue;
• DNA;
• swabs.

The question is usually not:

“Who owns this specimen?”

but:

Can the State lawfully obtain, preserve, test and produce the specimen as evidence?

Here, issues such as:

• lawful collection;
• consent;
• statutory authority;
• search/seizure;
• chain of custody;
• forensic methodology;
• authenticity;
• contamination;

become more important than conventional property ownership.

20. Chain of custody

For forensic specimens, chain of custody is critical.

A proper chain should establish:

Collection

↓

Identification

↓

Sealing

↓

Documentation

↓

Transportation

↓

Laboratory receipt

↓

Testing

↓

Preservation

↓

Production before court

Any unexplained break can be used to challenge the evidentiary reliability of the specimen.

The Tiwari DNA litigation illustrates the importance of controlled and confidential collection and sealed transmission to the laboratory.

21. Pathology specimens

A pathology specimen creates another category of dispute.

For example:

A patient undergoes surgery and a tumour is removed.

The hospital retains:

• tissue blocks;
• paraffin-embedded tissue;
• microscopic slides;
• diagnostic reports.

The patient may want the specimen for:

• second opinion;
• another hospital;
• expert review;
• litigation.

The hospital may argue that it has custody and professional responsibilities concerning the specimen.

This is precisely why custody and ownership should not automatically be treated as identical concepts.

The patient's rights may arise through:

• medical records;
• informed consent;
• contractual obligations;
• negligence law;
• consumer law;
• privacy law;
• applicable professional regulations;
• institutional policy.

22. Research specimens and commercialization

This is perhaps the most difficult category.

Suppose:

Patient provides blood

↓

Researcher isolates cells

↓

Cell line is developed

↓

Genetic discovery is made

↓

Patent is obtained

↓

Commercial product is developed.

The critical question becomes:

Does the donor own the resulting invention or commercial product merely because the original biological material came from the donor?

Cases such as Moore, Greenberg and Catalona show that the answer is not necessarily.

The legal analysis may instead focus on:

• informed consent;
• disclosure;
• intellectual-property law;
• contractual rights;
• fiduciary duties;
• benefit sharing;
• privacy;
• research ethics.

23. Specimen ownership and intellectual property

Another crucial distinction:

Specimen

The physical biological material.

Genetic information

Information derived from the specimen.

Invention

A new technical development based on research.

Patent

A legally recognized intellectual-property right.

These are four different things.

For example:

Patient's blood → DNA sequence → scientific discovery → diagnostic technology → patent.

Ownership of the original blood does not automatically establish ownership of every subsequent invention.

That distinction is central to Moore and Catalona.

24. Right to withdraw or destroy

ICMR's ethical framework is particularly significant here.

The ICMR handbook states that a donor has a right to ask for destruction/withdrawal of collected samples, subject to the framework governing the research and the practical/legal circumstances.

This means that specimen ownership can involve a right of control rather than simply the traditional property right to possess and sell.

That is an important modern concept:

Biological-material rights may be a bundle of rights rather than a simple all-or-nothing ownership interest.

25. Material Transfer Agreement (MTA)

When specimens are transferred between research institutions, an MTA is extremely important.

It should address:

• identity of specimens;
• permitted purpose;
• ownership;
• custody;
• secondary use;
• transfer to third parties;
• destruction;
• confidentiality;
• publication;
• intellectual property;
• commercial use;
• benefit sharing;
• return of specimens;
• applicable law;
• dispute resolution.

ICMR specifically recommends an MTA when biological specimens are transferred within or outside India.

26. Specimen ownership and privacy

A specimen can contain extraordinarily sensitive information.

A blood sample can reveal:

• genetic characteristics;
• disease susceptibility;
• familial relationships;
• ancestry;
• potential health risks.

Therefore, even if an institution has lawful custody of a specimen, that does not necessarily mean it can freely disclose the information derived from it.

The legal analysis should separately examine:

physical specimen + genetic information + identifiable personal data.

ICMR guidance expressly requires attention to privacy and confidentiality in biological-material and dataset management.

27. A hypothetical specimen-ownership lawsuit

Suppose Patient A gives blood to Hospital B for cancer diagnosis.

The hospital stores the blood.

Five years later:

1. Researcher C wants to use the sample.
2. The research could generate commercial profits.
3. Patient A objects.
4. Hospital B says it owns the sample.
5. Researcher C says the consent form permitted research.

The court would need to examine:

Issue 1

What did A consent to?

Issue 2

Was research authorized?

Issue 3

Was future/secondary research authorized?

Issue 4

Was commercialization disclosed?

Issue 5

Who has custody?

Issue 6

Who has proprietary rights?

Issue 7

Does A have a right to destruction/withdrawal?

Issue 8

Does the use infringe privacy?

Issue 9

Was the sample anonymized?

Issue 10

Was an MTA required?

The answer cannot be determined simply by saying:

“The sample came from the patient.”

28. Causes of action in specimen litigation

Depending upon the facts, litigation might involve:

A. Declaration

A declaration concerning ownership or rights over the specimen.

B. Injunction

To prevent:

• testing;
• transfer;
• destruction;
• publication;
• commercialization.

C. Privacy claim

Where personal/genetic information is improperly used or disclosed.

D. Breach of confidentiality

Where information supplied in a medical relationship is improperly disclosed.

E. Negligence

For loss, destruction or improper handling of a specimen.

F. Breach of contract

Where consent forms, research agreements or MTAs create contractual obligations.

G. Medical negligence

Where improper handling of a diagnostic specimen causes patient harm.

H. Constitutional remedies

Where State action implicates privacy, dignity or personal liberty.

29. Most important legal distinction

The safest way to answer a specimen-ownership problem is:

Do not equate the biological origin of the specimen with legal ownership.

A specimen can simultaneously involve:

• donor's personal/constitutional interests;
• institutional custody;
• contractual rights;
• research rights;
• intellectual-property interests;
• privacy interests;
• evidentiary interests.

30. Examination-ready legal proposition

You can write:

“Specimen ownership is a context-dependent legal question. The removal of biological material from the human body does not invariably result either in complete retention of ownership by the donor or in complete ownership by the collecting institution. Courts examine the purpose of collection, informed consent, contractual arrangements, statutory provisions, custodial obligations, privacy interests and the nature of the material. Indian ethical guidance treats participants as owners of biological samples and institutions as custodians/trustees, while comparative jurisprudence demonstrates differing approaches: Moore v. Regents restricted a conversion/property claim while recognizing disclosure duties; Washington University v. Catalona treated donated research specimens as belonging to the university; and Yearworth v. North Bristol NHS Trust recognized a property interest in stored sperm. Indian DNA jurisprudence, including Goutam Kundu, Sharda, and Rohit Shekhar, further demonstrates that bodily samples engage privacy and dignity interests and may be subject to judicial direction when scientifically and legally necessary.”

Key cases to remember

1. Goutam Kundu v. State of West Bengal, (1993) 3 SCC 418 — DNA/blood testing should not be ordered routinely.
2. Sharda v. Dharmpal, (2003) 4 SCC 493 — medical examination and privacy; courts may order examination in appropriate circumstances.
3. Bhabani Prasad Jena v. Convenor, Orissa State Commission for Women, (2010) 8 SCC 633 — cautious approach to DNA testing.
4. Rohit Shekhar v. Narayan Dutt Tiwari, Delhi HC (2012) — judicial direction for DNA testing in paternity litigation. 
5. Narayan Dutt Tiwari v. Rohit Shekhar — Supreme Court directions concerning confidential collection and sealed transmission of DNA sample. 
6. Moore v. Regents of University of California, 793 P.2d 479 (Cal. 1990) — no conversion claim merely from patient's cells, but disclosure obligations recognized. 
7. Greenberg v. Miami Children's Hospital, 264 F. Supp. 2d 1064 (S.D. Fla. 2003) — limits on donors' proprietary claims over donated research material. 
8. Washington University v. Catalona, 490 F.3d 667 (8th Cir. 2007) — research institution held ownership of donated biological samples under applicable state law. 
9. Yearworth v. North Bristol NHS Trust, [2009] EWCA Civ 37 — stored sperm treated as property of its producer for relevant negligence/bailment purposes. 

Bottom line

Indian law does not presently provide a simple “the patient owns every specimen” rule through a comprehensive statute. However, the ICMR ethical framework expressly states that participants own their biological samples/data and institutions/biobanks act as custodians or trustees. In actual litigation, the consent document, purpose of collection, custody arrangements, privacy interests, applicable statute, and intended use of the specimen can be decisive.

For a law-school answer, the strongest comparative structure is ICMR → Goutam Kundu → Sharda → Rohit Shekhar → Moore → Catalona → Yearworth, followed by an analysis of ownership vs custody vs privacy vs evidentiary use.